Cargando…

Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System

OBJECTIVES: The study aimed to investigate the prevalence and demographic characteristics of an immune checkpoint inhibitor (ICI)-related thyroid dysfunction (ICI-TD), and to explore risk factors of poor clinical outcome using data from the US Food and Drug Administration (FDA) Adverse Event Reporti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Difei, Yao, Jun, Yuan, Geheng, Gao, Ying, Zhang, Junqing, Guo, Xiaohui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895746/ https://www.ncbi.nlm.nih.gov/pubmed/35641200 http://dx.doi.org/10.1093/oncolo/oyab043

Ejemplares similares

Thyroid-related adverse events induced by immune checkpoint inhibitors
por: Chera, Alexandra, et al.
Publicado: (2022)

Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System
por: Kong, Qingli, et al.
Publicado: (2023)

Editorial: Decoding checkpoint inhibitor-induced immune-related adverse events, volume II
por: Burnett, Deborah L., et al.
Publicado: (2023)

Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management
por: Zhan, Ling, et al.
Publicado: (2021)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
por: Meng, Long, et al.
Publicado: (2021)

Clinical characteristics and the prognosis of diabetic foot in Tibet: A single center, retrospective study
por: Yuan, Xiaoyong, et al.
Publicado: (2023)

Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency
por: Katakura, Yukino, et al.
Publicado: (2021)

Immune Related Adverse Events of the Thyroid – A Narrative Review
por: Muir, Christopher A., et al.
Publicado: (2022)

Multiscale entropy and small-world network analysis in rs-fMRI — new tools to evaluate early basal ganglia dysfunction in diabetic peripheral neuropathy
por: Yuan, Geheng, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
por: Di Molfetta, Sergio, et al.
Publicado: (2021)

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database
por: Liu, Lulu, et al.
Publicado: (2022)

Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series
por: Ganta, Nagapratap, et al.
Publicado: (2022)

Risk Factors for Diabetic Peripheral Neuropathy, Peripheral Artery Disease, and Foot Deformity Among the Population With Diabetes in Beijing, China: A Multicenter, Cross-Sectional Study
por: Liu, Jiayi, et al.
Publicado: (2022)

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2022)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
por: Hsu, Fu-Shun, et al.
Publicado: (2017)

The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors
por: Karimian, Zahra, et al.
Publicado: (2020)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
por: Zhou, Chaozheng, et al.
Publicado: (2023)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Ding, Lingqing, et al.
Publicado: (2022)

Thyroid autoimmunity and adverse pregnancy outcomes: A multiple center retrospective study
por: Xu, Yun, et al.
Publicado: (2023)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

Thyroid dysfunction associated with iodine-contrast media: A real-world pharmacovigilance study based on the FDA adverse event reporting system
por: Huang, Lu, et al.
Publicado: (2023)

A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors
por: Lal, Jessica Castrillon, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Induced Endocrine Adverse Events in Cancer Patients at a Tertiary Care Center in Saudi Arabia
por: Alqahtani, Ali, et al.
Publicado: (2023)

Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database
por: Cui, Chanjuan, et al.
Publicado: (2022)

Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors
por: Muir, Christopher Alan, et al.
Publicado: (2021)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2021)

Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival: results of an exploratory study
por: Lee, Hanna J., et al.
Publicado: (2023)

A Tale of Immune-Related Adverse Events With Sequential Trials of Checkpoint Inhibitors in a Patient With Metastatic Renal Cell Carcinoma
por: Singh, Vinit, et al.
Publicado: (2020)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
por: Huang, Jing, et al.
Publicado: (2020)

Adverse Events in Robotic Surgery: A Retrospective Study of 14 Years of FDA Data
por: Alemzadeh, Homa, et al.
Publicado: (2016)

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database
por: Poluzzi, Elisabetta, et al.
Publicado: (2013)

Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System
por: Sanagawa, Akimasa, et al.
Publicado: (2018)

Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database
por: Asano, Hiroki, et al.
Publicado: (2023)

Association of Mild Thyroid Dysfunction and Adverse Prognosis Among Chinese Patients With Acute ST Segment Elevation Myocardial Infarction
por: Li, Mei-Fang, et al.
Publicado: (2022)

Thyroid Dysfunction and Sleep Disorders
por: Green, Max E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0ljircp85j6ltgu95hdbdcedoe